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ABSTRACT
Anti-IgE and anti-Fce RI a chain auto-antibodies have
been detected in the sera of atopic and non-atopic sub-
jects; however, the biological activity of these
auto-antibodies is still unclear. These two kinds of auto-
antibodies were examined in atopic dermatitis (AD)
patients. In results, 12 of 92 AD patients have the anti-
IgE, eight have the anti-Fce RI a auto-antibodies and
two have both auto-antibodies. Furthermore, biological
characterization of these auto-antibodies has been 
performed. In results, three of 12 samples with the anti-
IgE auto-antibodies exhibited inhibitory activity for
IgE-Fce RI a binding. Two of the eight samples with the
anti-Fce RI a auto-antibodies and one of the two
samples with both auto-antibodies had histamine
releasing activity. It is documented here that both anti-
IgE and anti-Fce RI a auto-antibodies were detected in
some AD patients, some anti-IgE auto-antibodies had
inhibitory activity for IgE-Fce RI binding and also hista-
mine releasing activity was detected in the anti-Fce RI a
chain auto-antibody.
Key words: atopic dermatitis, auto-antibody, high
affinity IgE receptor, immunoglobulin E.
INTRODUCTION
Anti-IgE auto-antibodies have been detected in patients
with atopic and non-atopic diseases.1–5 However, the bio-
logical activities of these auto-antibodies are still unclear.
There are actually controversial reports on the histamine
releasing activity of the anti-IgE auto-antibodies.4,6,7
Although these auto-antibodies have been considered
anaphylactogenic, low levels of anti-IgE auto-antibodies
have also been found in normal individuals.8–10 Vogel
et al. have documented that the epitopes of anti-IgE
auto-antibodies are mostly idiotypic determinants and
few react specifically with the CH3 domain of IgE, in
which the receptor binding region is located.11
In contrast, anti-Fce RI a chain auto-antibodies have
been detected in the sera of patients with chronic
urticaria.12 These anti-Fce RI a chain auto-antibodies func-
tion as histamine-releasing factors in these patients. Both
the anti-IgE and anti-Fce RI a chain auto-antibodies have
been reported in chronic urticaria and the anti-Fce RI a
chain auto-antibodies exert higher histamine-releasing
activity. These reports led us to examine the occurrence of
the anti-IgE and anti-Fce RI a auto-antibodies in patients
with atopic dermatitis (AD). These antibodies may modu-
late clinical symptoms of AD patients according to their
biological activities.
In general, auto-antibodies are polyclonal and recog-
nize various epitopes of the same antigen. The different
epitopes may contribute to different biological activities
of the auto-antibodies. The histamine-releasing activity of
anti-IgE and anti-Fce RI a chain auto-antibodies possibly
influences the severity of AD. Another possible activity
of these auto-antibodies is the inhibitory activity against
IgE-Fc e RI a binding. The anti-IgE auto-antibodies that
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recognize the CH3 domain of IgE may inhibit IgE binding
to Fce RI a . This type of anti-IgE auto-antibodies may
attenuate the symptoms of AD by blocking IgE binding to
the Fce RI a chain.
In the present study, we investigated both auto-
antibodies in AD patients to make a detailed analysis for
pathophysiology of AD.
METHODS
Patients and sera
Serum samples from 92 patients with AD and six normal
volunteers were collected and stored at – 20°C until use.
When subjected to enzyme-linked immunosorbent assay
(ELISA), all samples were 1:20 diluted with phosphate-
buffered saline (PBS, pH 7.4) containing 0.03% human
serum albumin (HSA).
Antibodies and reagents
Immunoglobulin E myeloma protein was purified from
the serum of an IgE myeloma patient as described previ-
ously.13–15 Two types of mouse antihuman Fce RI a chain
monoclonal antibodies, CRA2 and biotinylated CRA1,
were used for ELISA assays. CRA2 competes with IgE for
binding to the Fce RI a , while CRA1 does not (described
elsewhere).16
A recombinant soluble form of the human Fce RI a
chain ectodomain (soluble a ) was prepared as previously
described.17–19
Monoclonal mouse antihuman IgE and horseradish
peroxidase (HRP)-labeled goat antihuman IgG antibodies
were purchased from Cappel (Durham, NC, USA) and
HSA from Sigma Chemical Co. (St Louis MO, USA).
Diaminobenzidine (DAB) color development was per-
formed by using VECTASTAIN-ABC kit® (Funakoshi, Tokyo,
Japan), according to the manufacturer’s instruction.
Secreted histamine was measured by using Histamine
Release Test® (HRT; Miles/Hollister-Stier, Spokane, WA,
USA) following the manufacturer’s instructions.
Detection of anti-IgE and anti-Fce RI a
auto-antibodies by ELISA
Anti-IgE and anti-Fce RI a chain auto-antibodies were
evaluated by ELISA.
For the detection of anti-IgE auto-antibodies, each well
of the ELISA plate (Costar, Cambridge, MA, USA) was
coated with human IgE by incubation with 50 m L IgE-con-
taining buffer (2 m g/mL in 0.01 mol/L PBS, pH 7.4) at
4°C for 12 h. The plate was washed 3 times with 0.05%
Tween 20-PBS and 0.3% HSA-PBS solution was added 
to each well to block non-specific binding of the serum
immunoglobulins. After incubation at 37°C for 4 h, the
plate was washed 3 times and then 50 m L of sample sera
(1:20 diluted with 0.03% HSA-PBS) was added to each
well in triplicate. The plate was incubated at 37°C for 1 h
and washed 3 times. Horseradish peroxidase-labeled
antihuman IgG (diluted 1:2000) was added to each well
and the plate was incubated at 37°C for 1 h and washed
3 times. o-Phenylenediamine dihydrochloride (OPD; 
100 m L of 1 mg/mL; Wako pure chemical industries,
Osaka, Japan) in citrate buffer containing 0.0075% (w/v)
H2O2 was added to each well. After 15 min color devel-
opment, the enzymatic reaction was stopped by adding
100 m L sulfuric acid (2 mol/L). Optical density (OD) at
492 nm wavelength was measured by an ELISA micro-
plate reader (Bio-Rad, Richmond, CA, USA).
Anti-Fce RI a chain auto-antibody was evaluated basi-
cally in the same way as described above, except that the
coated antigen was the soluble a (50 m L of 3.6 m g/mL
solution in 50 mmol/L bicarbonate buffer, pH 9.4) for
this ELISA.
Second screening for the anti-Fce RI a chain
auto-antibodies by ELISA
To exclude the effects of IgE-anti-IgE auto-antibody
complexes on measuring the anti-Fce RI a chain auto-
antibodies at the first screening, another ELISA system
was adopted for the second screening.
Each well of the ELISA plate was coated with 50 m L
CRA2 (2 m g/mL in 50 mmol/L bicarbonate buffer, pH
9.4) at 4°C for 12 h, washed 3 times and blocked with
0.3% HSA. Then, 50 m L of the soluble a (1.8 m g/mL in
0.03% HSA-PBS) was added to each well and the plate
was incubated at 37°C for 1 h. After 3 washes, 1:20
diluted sera (which showed substantially higher OD titer
at the first screening of anti-Fce RI a chain auto-antibody)
were added to each well in triplicate and the plate was
incubated at 37°C for 1 h. Finally, HRP-labeled anti-
human IgG antibody was added to each well and the
reaction mixture was developed with substrate as
described earlier.
Preparation of the serum IgG fraction
The auto-antibody-positive sera were heat inactivated
at 56°C for 2 h to inactivate serum IgE.20 After heat
inactivation, IgG fractions of the serum samples were
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semipurified by salt fractionation with 50% saturated
ammonium sulfate (Wako pure chemical industries). 
After salt fractionation (twice), protein concentrations of
the samples were adjusted to 10 mg/mL with 0.03%
HSA-PBS. Purity of IgG was checked by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE).
Histamine-releasing assay
Histamine-releasing activity of the auto-antibody positive
samples was assessed by measuring the released hista-
mine from peripheral blood leukocytes with these
auto-antibodies using HRT® test (Miles/Hollister-Stier).
Briefly, 35 m L of leukocytes from peripheral blood from
one AD patient (auto-antibody negative by ELISA), were
added to each well, to which 15 m L of IgG fractions of the
positive or normal samples were added. After 30 min
incubation at 37°C, the released histamine from baso-
phils in the peripheral blood was precipitated by addition
of the indicated concentration of the HRP-labeled anti-
histamine antibody. The HRP-labeled antihistamine
antibody that exceeded the amount of histamine was
adsorbed by the histamine-coated plastic pegs. This
excess HRP-labeled antihistamine antibody was color
developed. High histamine release is shown as low OD
titer and low histamine release as high OD titer by mea-
suring OD at 410 nm wavelength.
Evaluation of inhibitory activity of the anti-IgE
auto-antibodies against IgE binding to the
Fce RI
The ELISA plate was coated with 50 m L human IgE
(4 m g/mL in 0.03% HSA-PBS) at 4°C for 12 h. After 3
washes and blocking with 0.3% HSA-PBS, the diluted
samples (1:50–1:500 diluted with 0.03% HSA-PBS) were
added to each well and the plate was incubated at 37°C
for 1 h. After 3 washes, 50 m L of the soluble a (900
ng/mL in 0.03% HSA-PBS) was added to each well and
the plate was incubated at 37°C for 1 h. After 3 washes,
50 m L biotinylated-CRA1 (4 m g/mL in PBS) was added to
each well and the plate was incubated at 37°C for 1 h.
After washes, the avidine-peroxidase solution was added
to each well and DAB color development was performed
using the VECTASTAIN-ABC kit (Funakosi) according to
the manufacturer’s instructions.
RESULTS
Serum anti-IgE auto-antibodies in AD patients
We examined sera of 92 AD patients and six normal vol-
unteers for their serum IgG activity for binding to human
IgE. The levels of the anti-IgE auto-antibodies for each
group are shown as OD values. The OD values of AD
samples were distributed over a wide range; however,
those of normal volunteers showed a narrow distribution
(Fig. 1). The average of each group demonstrated no 
statistical difference. Samples that showed a higher OD
titer than the mean + 2 SD were classified as positive.
Twelve of 92 (13%) were evaluated as positive.
Anti-Fc e RI a chain auto-antibodies in the sera
of AD patients
The same 92 AD samples were subjected to the first
screening for anti-Fce RI a chain auto-antibodies. The
values of the anti-Fce RI a chain auto-antibodies for each
group are shown in Fig. 2. After the first screening, 15
samples were picked up as positive (higer OD titer than
the mean + 2 SD) for binding to the soluble a . However,
by the ELISA assay, using the soluble a as antigen, not
only anti-Fce RI a chain auto-antibodies but also the IgG
in IgE-anti-IgE auto-antibody complex was detected by
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Fig. 1 Levels of anti-IgE auto-antibody. Sera were assessed
by enzyme-linked immunosorbent assay using human IgE-
coated plates and horseradish peroxidase-labeled anti-human
IgG antibody as described in Methods. The values of anti-IgE
auto-antibody are indicated as optical density (OD) titer. The
shaded area represents values under the mean + 2 SD OD
titer of healthy individuals. The horizontal bars are the means
of each group. No significant differences between the normal
group and the atopic dermatitis (AD) group were found by
t-test.
the HRP-labeled anti-IgG antibody. Therefore, the second
screening was performed for 15 of 92 positive samples
as described in Methods.
Because the IgE-binding site of the soluble a was occu-
pied by CRA2, IgE-anti-IgE auto-antibody complexes
could not bind to the soluble a and false positive IgE-
anti-IgE auto-antibody complexes could be excluded by
this ELISA assay (second screening).
At the second screening, seven of the 15 samples that
were positive at the first screening ELISA diminished in
their ability to bind to the soluble a , as shown in Fig. 3.
These results indicate that the anti-IgE auto-antibodies
(IgG class) formed the IgE-anti-IgE complexes and that
some IgE-anti-IgE complexes in the sera of AD patients
actually bound to the soluble a . In other words, some
anti-IgE auto-antibodies did not affect the a chain
binding site that is located in the CH3 domain of IgE.
From the positive sera in anti-IgE and/or anti-Fce RI a
chain auto-antibodies, IgG fractions were semipurified
and subjected to further biochemical assays.
Histamine-releasing activity of the auto-
antibodies in AD patients
All semipurified IgG fractions of samples that contained
either auto-antibody were examined for their histamine-
releasing activity from peripheral blood basophils of AD
patients.
A mouse antihuman IgE monoclonal antibody was
used as a positive control for the histamine-releasing
assay (Fig. 4). Compared with the positive control, three
samples (Fig. 4) presented histamine-releasing activity
and showed a lower OD titer than the control.
Inhibitory activity of anti-IgE auto-antibodies
against IgE binding to Fce RI
Anti-IgE auto-antibodies were also evaluated for their
inhibitory activity against the IgE-Fce RI a binding.
To catch anti-IgE auto-antibodies, an ELISA plate
was coated with IgE and semipurified IgG fractions were
added to the wells.
Detection of the soluble a with biotinylated CRA1
revealed that low OD titer samples contained the
inhibitory anti-IgE auto-antibody, because the CRA1 does
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Fig. 2 Levels of anti-Fce RI a chain auto-antibody. Sera were
assessed by enzyme-linked immunosorbent assay using the
soluble a -coated plates and horseradish peroxidase-labeled
anti-human IgG antibody as described in Methods. The values
of anti-Fce RI a chain auto-antibody are indicated as optical
density (OD) titer. The shaded area represents values under the
mean + 2 SD OD titer of healthy individuals. The horizontal
bars are the means of each group. No significant differences
between the normal group and the atopic dermatitis (AD)
group were found by t-test.
Fig. 3 Second screening for the anti-Fce RI a chain auto-
antibody to exclude false positive samples. To exclude the con-
tamination of IgE-anti IgE auto-antibody complexes, first, CRA2
(anti-Fce RI a mAb, competitive with IgE) coated plates were
incubated with the soluble a . Then, sera were incubated 
with these plates and detection of ‘true’ anti-Fce RI a chain 
auto-antibodies was performed by addition of horseradish
peroxidase-labeled anti-human IgG as described in Methods.
Seven of 15 samples that showed a positive OD titer at the first
anti-Fce RI a chain auto-antibody screening fell within + 2 SD
of healthy control individuals (Ctr). The horizontal line indicates
the + 2 SD OD titer of healthy individual serum samples.
not compete with IgE for the binding to the Fce RI and can
bind even IgE-bound Fce RI.
As shown in Fig. 5, three samples actually had the
inhibitory anti-IgE (lower than the mean – 2 SD of the
control) and the dilution of samples made their inhibitory
activity decrease in a dilution-dependent manner.
A summary is presented in Table 1. Twelve of 92 (13%)
AD patient samples had anti-IgE auto-antibodies and
eight of 92 (8.7%) had anti-Fce RI a chain auto-antibod-
ies. Two samples had both anti-IgE and anti-Fce RI a
chain auto-antibodies. Three of 12 (25%) anti-IgE auto-
antibody positive samples showed inhibitory activity
against IgE-soluble a binding and three samples positive
for both anti-IgE and anti-Fce RI a chain auto-antibodies
possessed histamine-releasing activity. All of the releasing
assay positive samples contained anti-Fce RI a chain
auto-antibodies (one sample had both anti-IgE and anti-
Fce RI a chain auto-antibodies).
DISCUSSION
Anti-IgE auto-antibodies have been detected in patients
with atopic diseases (asthma, atopic dermatitis, allergic
conjunctivitis)2–4 and also in patients with chronic
urticaria.5,6,9 Recently, anti-Fce RI a chain auto-antibodies
have also been reported in patients with chronic
urticaria.12
In the present study, we investigated whether the anti-
Fce RI a chain auto-antibodies occurred in sera of AD
patients. Thirteen percent of patients with AD had anti-IgE
and 8.7% had anti-Fce RI a chain auto-antibodies.
According to previous reports, the proportion of the
anti-IgE auto-antibody positive sera varied from 20 to
80% in the population.3,4,8,21 However, our results show a
lower level of positives than previous reports. One pos-
sible explanation for this discrepancy is that the reagents
used for blocking non-specific binding varied between
experiments. In our study, when we used bovine serum
albumin (BSA)-PBS as blocking and dilution reagents, 
a false positive reaction was detected. Using HSA instead
of BSA, we could reduce OD titers of false positive
samples to within the mean + 2 SD of those in normal
volunteers. False positive reactions may be attributable to
the IgG reacting with the proteins contained in the block-
ing reagents, such as casein. Thus, we used HSA (IgG
free) as a blocking and dilution reagent in screening to
exclude false positives.
The other problem in detecting auto-antibodies is the
very small quantities of auto-antibodies that are approxi-
mately equimolar to IgE.22,23 In such cases, the anti-IgE
auto-antibodies that form the IgG-IgE immune complexes
in the sera or in vitro incubation24 are underestimated by
our methods.
There is a variety of autoimmune diseases in which
pathogenic auto-antibodies play an important role. For
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Fig. 4 Histamine-releasing activity of the auto-antibodies in
atopic dermatitis patients. Histamine-releasing activity of the
auto-antibodies was assessed by measuring the released
histamine from peripheral blood leukocytes with these auto-
antibodies using Histamine Releasing Test (HRT®). Low optical
density (OD) titer means high histamine-releasing activity. Three
samples ( ) represent histamine-release activity. Two samples
are single positive for the anti-Fce RI a chain auto-antibody and
one sample is positive for the both auto-antibodies. Ctr, healthy
individual sample.
Fig. 5 Inhibitory activity of anti-IgE auto-antibodies against
IgE binding to the Fce RI a chain. A human IgE-coated plate
was incubated with semipurified sera, then the soluble a was
added to the plate. Detection of the captured soluble a was
performed by biotinylated CRA1 (anti-Fce RI a mAb, non-
competitive with IgE). Three samples under the mean – 2 SD of
the healthy individual (---) have inhibitory activity against IgE-
Fce RI a binding. Dilution of the samples made their inhibitory
activity decrease in a dilution dependent manner. Ctr, healthy
individual sample.
example, in pemphigus vulgaris, antidesmoglein III 
auto-antibodies attack the epidermal cell components,
causing acantholysis and erosion of the skin or mucosa.25
In Graves’ disease, antithyroid hormone receptor auto-
antibodies mimic the action of thyroid-stimulating
hormone.26
However, the functional roles of anti-IgE auto-antibod-
ies are still unclear. Because of difficulty in purifying
anti-IgE auto-antibodies that occur as immune com-
plexes, estimations of the function of anti-IgE auto-
antibodies still give conflicting results.27,28 In the present
study, we could not detect the anti-IgE auto-antibodies
that had histamine-releasing activity in peripheral blood
basophils of AD patients, but we detected the anti-IgE
auto-antibodies that possessed inhibitory activity for the
IgE-Fc e RI binding. One possible explanation for the
difference in biochemical activities of the anti-IgE auto-
antibodies may be the variation on the epitopes of IgE
that were recognized by these auto-antibodies.29,30
Most of the murine monoclonal anti-IgE auto-
antibodies were directed against the different idiotypic
determinants and some clones reacted with the CH3
domain of the Fce chain.11 The possible role of anti-idio-
typic auto-antibodies to IgE may be in the regulation of
the IgE system. Both the histamine-releasing activity and
the inhibitory activity for IgE binding to the Fce RI are
attributable to the anti-IgE auto-antibody recognizing the
receptor binding site located in the CH3 domain of the
Fce chain.
The occurrence of true ‘blocking’ auto-antibody in pa-
tients with atopic dermatitis has also been suggested.24,28
Stadler et al. have described that these non-anaphylacto-
genic type anti-IgE auto-antibodies may play a role in
modulating IgE biosynthesis28 and serve the purpose of
clearing allergen-IgE complexes from circulation.
Our data indicate that some anti-IgE auto-antibodies
have inhibitory activity for IgE-Fce RI a binding. This activ-
ity may be due to the anti-IgE auto-antibody being
directed against the binding site located in the CH3
domain of IgE, as it has been reported that the anti-IgE
auto-antibodies in the sera of AD patients are mainly
directed to the CH3 domain.30
There were no correlations between any clinical mani-
festations examined and the auto-antibodies (data not
shown). For example, the severity of skin eruption or
serum IgE levels of patients who had inhibitory anti-IgE
auto-antibodies were not significantly different from those
of the patients with no auto-antibodies, although the
samples with the inhibitory anti-IgE auto-antibody were
from only three cases.
Both anti-IgE and anti-Fce RI a chain auto-antibodies
have been detected in patients with chronic urticaria.5,12
According to these reports, anti-Fce RI a chain auto-
antibodies worked as histamine-releasing factors in
patients with chronic urticaria. We also detected both
auto-antibodies in patients with AD. Three of 92 sera
from patients with AD showed histamine-releasing
activity. All of these three sera had anti-Fce RI a chain
auto-antibodies and one of the 3 also had anti-IgE auto-
antibody. Most samples with anti-IgE auto-antibodies 
did not induce histamine release from basophils of AD
patients. Our results indicate that the anti-Fce RI a chain
auto-antibodies are the main factor that causes hista-
mine release.
According to previous studies,31,32 detectable amounts
of anti-Fce RI a auto-antibody are only in a subset of
chronic urticaria patients. In contrast, in the present study,
we detected anti-Fce RI a auto-antibody in AD patients.
Recently, Horn et al.33 have reported that the anti-Fce RI a
auto-antibody is a natural auto-antibody and serves as
the parental antibody for tetanus toxoid. In agreement
with latter reports, our data also indicates that the anti-
Fce RI a auto-antibody is not the specific auto-antibody of
chronic urticaria. We could not detect anti-Fce RI a auto-
antibody in normal subjects. This may be due to the
number of the tested samples.
The positive rate of anti-Fce RI a auto-antibody in our
results was lower than previous reports. This may be
explained by the methodology we used. For coating the
soluble a on the plate, we adopted the anti-Fce RI a chain
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Table 1 Anti-IgE and anti-Fce RI a chain auto-antibodies in AD patients
Anti-IgE auto-antibody Anti-Fce RI auto-antibody Both auto-antibodies
No. antibody positive samples 12/92* 8/92* 2/92*
No. samples with inhibitory activity against IgE binding 3/12† ND ND
No. samples with histamine-releasing activity 0/12† 2/8‡ 1/2§
*No. auto-antibody positive samples/Total no. samples; †no. assay positive samples/no. anti-IgE auto-antibody single positive samples;
‡no. assay positive samples/no. anti-Fce RI a chain auto-antibody single positive samples; §no. assay positive samples/no both auto-antibody positive
samples. AD, atopic dermatitis; ND, not done.
mouse antibody (CRA2), after coating the plate with
soluble a . Because CRA2 competes with IgE for the
binding site on the a chain, we could avoid the false pos-
itive detection of the IgE with anti-IgE auto-antibody,
which recognizes epitopes of IgE other than the binding
site to the a chain. However, our ELISA method men-
tioned earlier has the limitation that theoretically the
anti-Fce RI a chain auto-antibodies, which specifically
recognize the IgE-binding site on the a chain, would be
excluded. So, the positive ratio in our results was lower
than that in previous reports.
In conclusion, both anti-IgE and anti-Fce RI a chain
auto-antibodies occurred in the sera of patients with AD.
Anti-Fce RI a chain auto-antibodies showed histamine-
releasing activity and some anti-IgE auto-antibodies had
inhibitory activity for IgE-Fce RI a binding. So far, we have
failed to detect any special relationship between the
clinical parameters of AD and these auto-antibodies. To
clarify the biological significance of these auto-antibod-
ies, further biological and clinical analyses remain to be
performed in future.
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